Boehringer Ingelheim and the Mary Tyler Moore Vision
1 day ago · Boehringer Ingelheim’s Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global ...
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative …
1 day ago · Boehringer Ingelheim’s Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
2024 half year results innovation progress | Boehringer Ingelheim
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported on Thursday significant progress in its pipeline across key therapeutic areas as it reached major milestones in the first half of the year. ... For the remainder of the year, more news is expected across the portfolio with data read-outs in oncology (Zongertinib ...
Press Releases - Boehringer Ingelheim
Oct 14, 2021 · Find the latest press releases from Boehringer Ingelheim on animal health, prescription medicine, pipeline and corporate news.
Boehringer Ingelheim reports strong growth in 2023 and …
Apr 16, 2024 · Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned. Research & Development (R&D) investments...
Media & Stories - Boehringer Ingelheim
Boehringer Ingelheim’s hub for providing you with the latest press releases, news, background stories, and further press material for download. Press Releases. October 14, 2024. Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare. Read more. October 09, 2024.
First half of 2023: Boehringer Ingelheim sees strong growth and ...
Aug 1, 2023 · INGELHEIM, Germany-- (BUSINESS WIRE)--Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health...
First half of 2022: Boehringer Ingelheim continues growth pace …
Aug 3, 2022 · Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half.
Boehringer Ingelheim achieves major milestone in chronic kidney …
Nov 3, 2023 · INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi).
Boehringer Ingelheim and IBM Collaborate to Advance …
Nov 28, 2023 · Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics.